New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems
- 1 February 2008
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (3), 901-907
- https://doi.org/10.1016/j.bmcl.2007.12.066
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- 1,2,4-Triazol-3-yl-thiopropyl-tetrahydrobenzazepines: A Series of Potent and Selective Dopamine D3 Receptor AntagonistsJournal of Medicinal Chemistry, 2007
- Selective Dopamine D3 Receptor Antagonists: A Review 2001-2005Recent Patents on CNS Drug Discovery, 2006
- Recent advances towards the discovery of dopamine receptor ligandsExpert Opinion on Therapeutic Patents, 2006
- Design and Synthesis of trans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro- 1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3 Receptor AntagonistJournal of Medicinal Chemistry, 2003
- Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport PropertiesJournal of Medicinal Chemistry, 2000
- Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neurolepticsNature, 1990